Biotech Values

[dewophile]

idix

thanks
i too thought the recent price action was shorting, now with there being a small chance for clinical data at EASL and a growing sense that if there were major milestones from GSK this year they might have been more forthcoming (ala zgen)

i have a position now and am hoping easl gives the stock some pop nonetheless w solid preclinical data much like last year